BioAdaptives Inc. (OTC: BDPT) has announced the approval of a human clinical trial for its weight management product, Zeranovia™, by an Institutional Review Board (IRB). The trial will be conducted in Las Vegas, Nevada, under the supervision of medical doctors.
Trial Design and Objectives
The initial phase of the clinical trial is designed to confirm the appropriate dosing regimen for Zeranovia™ and to monitor for any potential adverse side effects. The trial has already garnered significant interest, with the first stage fully subscribed. A subsequent stage will be opened to accommodate additional participants.
Zeranovia™ Composition and Development
Zeranovia™ is formulated as a high-protein blend incorporating vitamins, minerals, and a selection of five concentrated herbal supplements, four of which are adaptogens. According to BioAdaptives, the development of Zeranovia™ involved extensive laboratory work over nearly a year.
Management Perspective
James Keener, CEO of BioAdaptives™, emphasized the company's commitment to scientific validation, stating that less than 1% of nutraceuticals in the U.S. undergo human clinical trials, according to data from the National Institutes of Health's Office of Dietary Supplements (ODS). Keener anticipates that the human clinical trials will mirror the positive results observed during product development, potentially positioning Zeranovia™ as a natural alternative to synthetic treatments like GLP-1 and GIP medications.
About BioAdaptives, Inc.
BioAdaptives, Inc. is a nutritional products company focused on delivering solutions for enhanced quality of life, anti-aging, cell repair, and overall well-being. The company emphasizes research, customer insights, and sustainable practices.
